PMC:7507645 / 2045-2981 JSONTXT

{"project":"TEST0","denotations":[{"id":"32958075-214-219-1506658","span":{"begin":214,"end":215},"obj":"[\"21464078\"]"},{"id":"32958075-217-222-1506659","span":{"begin":217,"end":218},"obj":"[\"30003412\"]"},{"id":"32958075-238-243-1506660","span":{"begin":288,"end":289},"obj":"[\"21464078\", \"30003412\", \"25083264\", \"28615422\", \"24116964\"]"},{"id":"32958075-238-243-1506661","span":{"begin":563,"end":564},"obj":"[\"25083264\"]"},{"id":"32958075-75-80-1506662","span":{"begin":645,"end":646},"obj":"[\"26252585\"]"},{"id":"32958075-78-83-1506663","span":{"begin":648,"end":649},"obj":"[\"17261680\"]"},{"id":"32958075-81-86-1506664","span":{"begin":651,"end":652},"obj":"[\"29392600\"]"},{"id":"32958075-183-189-1506665","span":{"begin":753,"end":755},"obj":"[\"27837173\", \"29667112\"]"},{"id":"32958075-167-173-1506666","span":{"begin":928,"end":930},"obj":"[\"29667112\"]"},{"id":"32958075-171-177-1506667","span":{"begin":932,"end":934},"obj":"[\"24372457\"]"}],"text":"Individuals with chronic migraine (CM) frequently use acute headache medications, including triptans, ergot derivatives, opioids, and simple and combination analgesics, which can result in medication overuse (MO) [1, 2] and lead to greater disability and further reduced quality of life [1–5]. Preventive migraine therapy is recommended in patients with failure or overuse of acute medication, frequent attacks (≥4 headache days per month), headaches that interfere with daily routines despite acute treatment, or adverse events associated with acute treatments [3, 6]. Despite the potential benefits, preventive therapy is often underutilized [7, 8, 9], and persistence with treatment is often poor due to lack of efficacy or intolerable side effects [10–12]. New preventive therapies may improve patient lives with superior treatment efficacy and tolerability compared with previously available migraine preventive therapies [12, 13]."}

{"project":"2_test","denotations":[{"id":"32958075-21464078-60560865","span":{"begin":214,"end":215},"obj":"21464078"},{"id":"32958075-30003412-60560866","span":{"begin":217,"end":218},"obj":"30003412"},{"id":"32958075-21464078-60560867","span":{"begin":288,"end":289},"obj":"21464078"},{"id":"32958075-30003412-60560867","span":{"begin":288,"end":289},"obj":"30003412"},{"id":"32958075-25083264-60560867","span":{"begin":288,"end":289},"obj":"25083264"},{"id":"32958075-28615422-60560867","span":{"begin":288,"end":289},"obj":"28615422"},{"id":"32958075-24116964-60560867","span":{"begin":288,"end":289},"obj":"24116964"},{"id":"32958075-25083264-60560868","span":{"begin":563,"end":564},"obj":"25083264"},{"id":"32958075-26252585-60560869","span":{"begin":645,"end":646},"obj":"26252585"},{"id":"32958075-17261680-60560870","span":{"begin":648,"end":649},"obj":"17261680"},{"id":"32958075-29392600-60560871","span":{"begin":651,"end":652},"obj":"29392600"},{"id":"32958075-27837173-60560872","span":{"begin":753,"end":755},"obj":"27837173"},{"id":"32958075-29667112-60560872","span":{"begin":753,"end":755},"obj":"29667112"},{"id":"32958075-29667112-60560873","span":{"begin":928,"end":930},"obj":"29667112"},{"id":"32958075-24372457-60560874","span":{"begin":932,"end":934},"obj":"24372457"}],"text":"Individuals with chronic migraine (CM) frequently use acute headache medications, including triptans, ergot derivatives, opioids, and simple and combination analgesics, which can result in medication overuse (MO) [1, 2] and lead to greater disability and further reduced quality of life [1–5]. Preventive migraine therapy is recommended in patients with failure or overuse of acute medication, frequent attacks (≥4 headache days per month), headaches that interfere with daily routines despite acute treatment, or adverse events associated with acute treatments [3, 6]. Despite the potential benefits, preventive therapy is often underutilized [7, 8, 9], and persistence with treatment is often poor due to lack of efficacy or intolerable side effects [10–12]. New preventive therapies may improve patient lives with superior treatment efficacy and tolerability compared with previously available migraine preventive therapies [12, 13]."}